2,503 Shares in Globus Medical, Inc. (NYSE:GMED) Acquired by Aigen Investment Management LP

Aigen Investment Management LP acquired a new stake in shares of Globus Medical, Inc. (NYSE:GMED) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,503 shares of the medical device company’s stock, valued at approximately $207,000.

Several other large investors have also recently bought and sold shares of GMED. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Globus Medical by 2.5% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 5,637 shares of the medical device company’s stock valued at $403,000 after buying an additional 140 shares during the period. Farther Finance Advisors LLC grew its stake in Globus Medical by 230.5% in the third quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company’s stock valued at $39,000 after acquiring an additional 385 shares during the period. Crossmark Global Holdings Inc. increased its holdings in shares of Globus Medical by 6.0% in the third quarter. Crossmark Global Holdings Inc. now owns 7,750 shares of the medical device company’s stock worth $554,000 after acquiring an additional 436 shares in the last quarter. River Global Investors LLP increased its holdings in shares of Globus Medical by 0.7% in the third quarter. River Global Investors LLP now owns 47,067 shares of the medical device company’s stock worth $3,366,000 after acquiring an additional 331 shares in the last quarter. Finally, Lisanti Capital Growth LLC raised its position in shares of Globus Medical by 68.4% during the third quarter. Lisanti Capital Growth LLC now owns 24,915 shares of the medical device company’s stock worth $1,782,000 after purchasing an additional 10,120 shares during the period. Institutional investors own 95.16% of the company’s stock.

Insider Activity

In other news, CFO Keith W. Pfeil sold 14,167 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $88.29, for a total value of $1,250,804.43. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 18.54% of the stock is currently owned by insiders.

Globus Medical Price Performance

Shares of NYSE:GMED opened at $77.48 on Monday. The company’s 50-day moving average price is $85.90 and its two-hundred day moving average price is $79.77. Globus Medical, Inc. has a one year low of $49.33 and a one year high of $94.93. The stock has a market capitalization of $10.66 billion, a PE ratio of 103.31, a price-to-earnings-growth ratio of 1.61 and a beta of 1.19.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, February 20th. The medical device company reported $0.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.10. The business had revenue of $657.29 million for the quarter, compared to analyst estimates of $646.19 million. Globus Medical had a return on equity of 10.83% and a net margin of 4.09%. On average, analysts anticipate that Globus Medical, Inc. will post 3.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on GMED shares. Truist Financial boosted their price objective on Globus Medical from $85.00 to $90.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. Roth Mkm upped their price target on shares of Globus Medical from $100.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, December 17th. Barclays raised their price objective on shares of Globus Medical from $100.00 to $103.00 and gave the stock an “overweight” rating in a report on Monday, February 24th. Morgan Stanley raised shares of Globus Medical from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $83.00 to $100.00 in a research note on Monday, December 2nd. Finally, StockNews.com cut Globus Medical from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Globus Medical currently has an average rating of “Moderate Buy” and a consensus price target of $97.82.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.